Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer

Acta Radiologica

Volumn 49, Issue 3, 2008, Pages 295-302

  Axelsson, R ^a,b   Herlin, G ^a   Bth, M ^a   Aspelin, P ^a   Kolbeck K G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Lung cancer; radionuclide imaging; solitary pulmonary nodules; somatostatin

Indexed keywords

BENIGN LESION; CHEST RADIOGRAPHY; CHONDROSARCOMA; CLINICAL EXAMINATION; CLINICAL OUTCOME; CLINICAL SETTINGS; COLON CANCER; COMPUTED TOMOGRAPHY; DIAGNOSTIC VALUE; HIGH SENSITIVITY; LUNG CANCER; LUNG METASTASIS; PULMONARY NODULES; RADIONUCLIDE IMAGING; SOMATOSTATIN; TECHNETIUM-99M; WHOLE-BODY;

BIOLOGICAL ORGANS; COMPUTERIZED TOMOGRAPHY; DECISION MAKING; DIAGNOSTIC RADIOGRAPHY; ENDOSCOPY; NUCLEAR MEDICINE; RADIOLOGY; TECHNETIUM; TOMOGRAPHY;

DISEASES;

DEPREOTIDE TC 99M; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; TECHNETIUM COMPLEX;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FEMALE; HAMARTOMA; HUMAN; IMAGE ENHANCEMENT; LABORATORY DIAGNOSIS; LUNG; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; OBSERVER VARIATION; PNEUMONIA; PREDICTION AND FORECASTING; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HAMARTOMA; HUMANS; IMAGE ENHANCEMENT; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; OBSERVER VARIATION; ORGANOTECHNETIUM COMPOUNDS; PNEUMONIA; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 42449149598     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1080/02841850701793777     Document Type: Article

References (18)

1. Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med 2002;43:752-6. (Pubitemid 34663295)
2. Reubi JC, Laissue J, Krenning EP, Lamberts S W J. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical applications. J Steroid Biochem Molec Biol 1992;43:27-35.
3. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Sem Nucl Med 2002;32:84-91. (Pubitemid 34311074)
4. Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res 1998;58:1850-9. (Pubitemid 28217458)
5. Blum J, Handmaker H, Lister-James J, Rinne N, and the Neo Tect Solitary Pulmonary Nodule Study Group, A multicentre trial with a somatostatin analog 99m-Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117:1232-8. (Pubitemid 30321573)
6. Bååth M, Kölbeck KG, Danielsson R. Somatostatin receptor scintigraphy with 99m-Tc-depreotide (NeoSpect) in discriminating between malignant and benign lesions in the diagnosis of lung cancer. A pilot study. Acta Radiol 2004;45:833-9. (Pubitemid 44112694)
7. Shih WJ, Hirschowitz E, Bensadoun E, Woodring J, Ryo YU, Kraman S. Biodistribution on Tc-99m labeled somatostatin receptor-binding peptide (Depreotide, NeoTec) planar and SPECT studies. Ann Nucl Med 2002;16:213-9. (Pubitemid 34717573)
8. Marten K, Grabbe E. The challenge of the solitary pulmonary nodule. Diagnostic assessment with multislice spiral CT. Clin Imaging 2003;27:151-61.
9. Danielsson R. Bååth M, Svensson L, Forslöw U, Kölbeck KG. Imaging of regional lymph node metastases with 99m-Tc-depreotide in patients with lung cancer. Eur J Nucl Med Mol Imaging 2005;32:925-31. (Pubitemid 41205663)
10. Danielsson R, Bååth M, Kölbeck KG, Klominek J, Svensson L. Accumulation of 99m-Tc-Depreotide (Neospect) in axillary sweat glands. Clin Nucl Med 2003;28:789-90. (Pubitemid 38295216)
11. Grewal RK, Dadparvar S, Ju JQ, Babaria CJ, Cavariaugh T, Sherman M, et al. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J 2002;8:400-4.
12. Martins T, Lino JS, Ramos S, Oliveira L. 99m-Tcdepreotide scintigraphy in the evaluation of indeterminate pulmonary lesions: clinical experience. Cancer Biother Radiopharm 2004;19:253-9. (Pubitemid 38685123)
13. Khan D, Menda Y, Kernstine K, Bushnell D, McLaughlin K, Miller S, et al. The utility of 99m-Tcdepreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest 2004;125:494-501. (Pubitemid 38228428)
14. Rasmussen K, Madsen H, Rasmussen F, Rasmussen T, Baandrup U, Pilegaard H, et al. The value of HRCT and Tc-depreotide in the evaluation of pulmonary lesions. J Thorac Oncol 2006;1:296-301. (Pubitemid 47163980)
15. Naalsund A, Maublant J. The solitary pulmonary nodule - is it malignant or benign? Diagnostic performance of Tc-depreotide SPECT. Respiration 2006;73:634-41. (Pubitemid 44481480)
16. Thomas L, Balingit A, Morison D, Gilman M. Falsepositive technetium 99m depreotide scintigraphy resulting from round atelectasis. J Thorac Imaging 2003;18:97-9. (Pubitemid 38067283)
17. Goldsmith SJ, Kostakoglu L. Nuclear medicine imaging of lung cancer. Radiol Clin North Am 2000;38:511-24. (Pubitemid 30350450)
18. Ferran N, Ricart Y, Lopez M, Martinez-Ballarin I, Roca M, Gámez C, et al. Characterization of radiologically indeterminate lung lesions. 99mTc-depreotide SPECT versus 18F-FDG PET. Nucl Med Com 2006;27:507-14. (Pubitemid 44309712)